Cargando…

Phytoestrogens in Postmenopause: The State of the Art from a Chemical, Pharmacological and Regulatory Perspective

Phytoestrogens represent a diverse group of non-steroidal natural products, which seem to have some oestrogenic effects and are often marketed as food supplements. Population exposed to phytoestrogens is potentially increasing, in part because an unfavourable risk-benefit profile of Hormone Replacem...

Descripción completa

Detalles Bibliográficos
Autores principales:	Poluzzi, Elisabetta, Piccinni, Carlo, Raschi, Emanuel, Rampa, Angela, Recanatini, Maurizio, Ponti, Fabrizio De
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bentham Science Publishers 2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963458/ https://www.ncbi.nlm.nih.gov/pubmed/24164197 http://dx.doi.org/10.2174/09298673113206660297

Ejemplares similares

Use of phytoestrogens and effects perceived by postmenopausal women: result of a questionnaire-based survey
por: Girardi, Anna, et al.
Publicado: (2014)

Liver Injury with Ulipristal Acetate: Exploring the Underlying Pharmacological Basis
por: Gatti, Milo, et al.
Publicado: (2020)

Stroke, Migraine and Triptans: From Bedside to Bench
por: Raschi, Emanuel, et al.
Publicado: (2016)

Drug-Induced Renal Damage in Preterm Neonates: State of the Art and Methods for Early Detection
por: Girardi, Anna, et al.
Publicado: (2015)

Long-acting injectable antipsychotics: Six-month follow-up of new outpatient treatments in Bologna Community Mental Health Centres
por: Berardi, Lorenzo, et al.
Publicado: (2019)

Recurrence of pericarditis after influenza vaccination: a case report and review of the literature
por: Mei, Riccardo, et al.
Publicado: (2018)

Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment
por: Raschi, Emanuel, et al.
Publicado: (2020)

Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System
por: Raschi, Emanuel, et al.
Publicado: (2021)

Development of a Network-Based Signal Detection Tool: The COVID-19 Adversome in the FDA Adverse Event Reporting System
por: Fusaroli, Michele, et al.
Publicado: (2021)

Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance
por: Raschi, Emanuel, et al.
Publicado: (2020)

Observational research on sodium glucose co‐transporter‐2 inhibitors: A real breakthrough?
por: Raschi, Emanuel, et al.
Publicado: (2018)

Liver Injury with Nintedanib: A Pharmacovigilance–Pharmacokinetic Appraisal
por: Raschi, Emanuel, et al.
Publicado: (2022)

Phytoestrogens in postmenopausal indications: A theoretical perspective
por: Sunita, P., et al.
Publicado: (2011)

Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System
por: Fusaroli, Michele, et al.
Publicado: (2022)

Mesenchymal stromal cell-based therapy: Regulatory and translational aspects in gastroenterology
por: Dothel, Giovanni, et al.
Publicado: (2016)

Antipsychotics and Torsadogenic Risk: Signals Emerging from the US FDA Adverse Event Reporting System Database
por: Poluzzi, Elisabetta, et al.
Publicado: (2013)

Pro-Arrhythmic Potential of Oral Antihistamines (H1): Combining Adverse Event Reports with Drug Utilization Data across Europe
por: Poluzzi, Elisabetta, et al.
Publicado: (2015)

Risk of hospitalization from drug-drug interactions in the Elderly: real-world evidence in a large administrative database
por: Swart, Floor, et al.
Publicado: (2020)

Strategies and Tools for Supporting the Appropriateness of Drug Use in Older People
por: Lunghi, Carlotta, et al.
Publicado: (2022)

Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance
por: Raschi, Emanuel, et al.
Publicado: (2020)

Drug-induced liver injury: Towards early prediction and risk stratification
por: Raschi, Emanuel, et al.
Publicado: (2017)

Strategies for Early Prediction and Timely Recognition of Drug-Induced Liver Injury: The Case of Cyclin-Dependent Kinase 4/6 Inhibitors
por: Raschi, Emanuel, et al.
Publicado: (2019)

Deliberate Self-Poisoning: Real-Time Characterization of Suicidal Habits and Toxidromes in the Food and Drug Administration Adverse Event Reporting System
por: Fusaroli, Michele, et al.
Publicado: (2023)

Torsadogenic Risk of Antipsychotics: Combining Adverse Event Reports with Drug Utilization Data across Europe
por: Raschi, Emanuel, et al.
Publicado: (2013)

Assessing the Association of Pioglitazone Use and Bladder Cancer Through Drug Adverse Event Reporting
por: Piccinni, Carlo, et al.
Publicado: (2011)

Relationship between adverse drug reactions to antibacterial agents and the Klebsiella pneumoniae carbapenemase-producing (KPC) Klebsiella pneumoniae outbreak: insight from a pharmacovigilance study
por: Gatti, Milo, et al.
Publicado: (2019)

Serious adverse events with novel beta-lactam/beta-lactamase inhibitor combinations: a large-scale pharmacovigilance analysis
por: Gatti, Milo, et al.
Publicado: (2021)

Serotonin syndrome by drug interactions with linezolid: clues from pharmacovigilance-pharmacokinetic/pharmacodynamic analysis
por: Gatti, Milo, et al.
Publicado: (2020)

Protective effect of phytoestrogens on nonalcoholic fatty liver disease in postmenopausal women
por: Zhao, ChenLu, et al.
Publicado: (2023)

Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase
por: Gatti, Milo, et al.
Publicado: (2021)

The Contribution of National Spontaneous Reporting Systems to Detect Signals of Torsadogenicity: Issues Emerging from the ARITMO Project
por: Raschi, Emanuel, et al.
Publicado: (2015)

Risk–Benefit Profile of Direct-Acting Oral Anticoagulants in Established Therapeutic Indications: An Overview of Systematic Reviews and Observational Studies
por: Raschi, Emanuel, et al.
Publicado: (2016)

The Anti-Inflammatory, Phytoestrogenic, and Antioxidative Role of Labisia pumila in Prevention of Postmenopausal Osteoporosis
por: Nadia, M. E., et al.
Publicado: (2012)

Food choice and phytoestrogen consumption in women previously treated for postmenopausal breast cancer
por: Parry, BM, et al.
Publicado: (2008)

Anti-Atherosclerotic Effects of a Phytoestrogen-Rich Herbal Preparation in Postmenopausal Women
por: Myasoedova, Veronika A., et al.
Publicado: (2016)

The Complex Management of Atrial Fibrillation and Cancer in the COVID-19 Era: Drug Interactions, Thromboembolic Risk, and Proarrhythmia
por: Gatti, Milo, et al.
Publicado: (2020)

Pattern of drug use among preterm neonates: results from an Italian neonatal intensive care unit
por: Girardi, A., et al.
Publicado: (2017)

Preventive effects of phytoestrogens against postmenopausal osteoporosis as compared to the available therapeutic choices: An overview
por: Al-Anazi, Abdullah Foraih, et al.
Publicado: (2011)

Somatic-vegetative Symptoms Evolution in Postmenopausal Women Treated with Phytoestrogens and Hormone Replacement Therapy
por: ŢIŢ, Delia Mirela, et al.
Publicado: (2017)

Overview on postmenopausal osteoporosis and periodontitis: The therapeutic potential of phytoestrogens against alveolar bone loss
por: Jayusman, Putri Ayu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_86aor8db6ihhtn2j2dbrsb2vbr